Cardiomyocyte Differentiation Using Timed Wnt Pathway Modulation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing cardiomyocytes from pluripotent stem cells are not robust and reproducible across different cell lines, often requiring specific optimization and can be affected by non-specific compounds leading to reduced yield, variability, and undesired phenotypical changes.

Innovation Solution

A method involving the use of XAV-939 and a second compound, such as IWP-L6 or C59, in an aqueous medium to differentiate human pluripotent stem cells into cardiomyocytes, preferably ventricular cardiomyocytes, with optional Wnt-signaling agonists like CHIR-99021 and growth factors like IGF, to achieve a homogeneous and efficient cardiomyocyte population.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional differentiation methods are used to produce cardiomyocytes from pluripotent stem cells, then cardiomyocyte production can be achieved, but the process lacks robustness and reproducibility across different cell lines

Engineering Contradiction:
Improvereproducibility of cardiomyocyte differentiationVSAvoidapplicability to different stem cell lines
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by systematically optimizing the concentrations and combinations of small molecule compounds (such as CHIR99021, IWP2, XAV939, DLT) in the differentiation protocol. By adjusting these chemical parameters, the method achieves consistent cardiomyocyte differentiation across multiple pluripotent stem cell lines without requiring line-specific optimization, thereby resolving the contradiction between reliability and adaptability.

Inventive Principle:
Principle #35Parameter changes

2Productivity

If high concentrations of differentiation compounds are used to stimulate pluripotent stem cell differentiation, then differentiation efficiency is improved, but non-specific modulation of multiple targets occurs leading to reduced yield and undesired phenotypical changes

Engineering Contradiction:
Improvedifferentiation efficiencyVSAvoidnon-specific compound effects
Core Design Contradiction:
ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent segments the differentiation process into distinct temporal phases, each with specific compound combinations. By dividing the differentiation protocol into stages (e.g., mesoderm induction phase followed by cardiomyocyte specification phase), the method achieves high differentiation efficiency while minimizing non-specific effects, as each phase uses compounds targeted to specific developmental transitions rather than broad-spectrum high-concentration treatment.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent employs periodic action through time-dependent addition and removal of small molecule compounds during differentiation. Specific compounds are added at defined time points and removed after specific durations, creating a temporal pattern of exposure that maximizes differentiation efficiency while avoiding cumulative non-specific effects. This periodic treatment schedule resolves the contradiction between productivity and harmful effects.

Inventive Principle:
Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method provides a reproducible and efficient production of cardiomyocytes with high yield and minimal adverse effects, suitable for various stem cell sources, overcoming the challenges of variability and specificity issues in existing techniques.

Implementation Method 1

A method involving the use of XAV-939 and a second compound, such as IWP-L6 or C59, in an aqueous medium to differentiate human pluripotent stem cells into cardiomyocytes

Methodology Applied
Scientific EffectWnt signaling inhibition:

Implementation Method 2

optional Wnt-signaling agonists like CHIR-99021

Methodology Applied
Scientific EffectWnt signaling activation:

Data Source

PatentEP3964565B1An in vitro method of differentiating a human pluripotent stem cell population into a cardiomyocyte cell population
Publication Date: 2026.04.08 NCARDIA BV
  • EP3964565B1 patent drawingFigure 1
  • EP3964565B1 patent drawingFigure 2
  • EP3964565B1 patent drawingFigure 3

AI summary

The current invention relates to a method of differentiation of human pluripotent stem cells into a human stem-cell derived population of cardiomyocytes. The method comprises the use of specific combination of steps and compounds to induce and/or promote differentiation. The method also comprises steps directed to further maturation of the cardiomyocytes obtained with the method of the invention. Also provided are kits for use in a method of differentiation as well as cell